Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035581 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
A Phase 2 study, sponsored by AIM ImmunoTech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00035581 is a Phase 2 study that was terminated before completion, run by AIM ImmunoTech. The registered enrollment target is 16 participants.
The verdict
NCT00035581, a Phase 2 study, was terminated before completion, sponsored by AIM ImmunoTech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts \>300 and HIV-1 plasma RNA \>500 and \<30,000 copies/ml (PCR).
Interventions
- DRUG poly I-poly C12U
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2001-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035581
The ClinicalTrials.gov registry entry for NCT00035581 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIM ImmunoTech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which poly I-poly C12U is the first listed.
NCT00035581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035581 about?
NCT00035581 is a clinical study titled "Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART". This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts \>300 and HIV-1 plasma RNA \>500 and \<30,000 copies/ml (PCR).
What is the current status of trial NCT00035581?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2001-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00035581?
The interventions under investigation include: poly I-poly C12U (DRUG).
Who is sponsoring clinical trial NCT00035581?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.